Olverembatinib in people with liver problems
Treatments studied
Part of Digestive system clinical trials.
This trial tests how a drug called olverembatinib is processed by the body in people with different levels of liver impairment. It looks at how the liver condition affects the drug levels and safety, which may help find the right dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stable liver disease caused by hepatitis, alcohol, autoimmune hepatitis, or another condition, and it must be mild, moderate, or severe (Child-Pugh A, B, or C).
- Your weight must be between certain ranges, and your body mass index (BMI) must be between 18 and 30.
- You must agree to use effective birth control during the study and for 3 months after, if you are able to have children.
- Your blood counts and liver tests must be within specific limits, and you cannot have certain serious liver complications like active bleeding, severe ascites, or a liver transplant.
- You cannot have used certain medications, supplements, or alcohol within specific timeframes before the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies olverembatinib to treat certain blood cancers that have an FGFR1 rearrangement (a specific gene change). It’s for people whose disease is newly diagnosed, has progressed, or has come back, and who can safely take the study medicine and attend follow-up visits.
This Phase 2 trial tests olverembatinib plus blinatumomab for Philadelphia chromosome–positive (Ph+) ALL that is newly diagnosed. It aims to see how well this combination works and how safe it is for people who have not yet had standard leukemia medicines.
This study looks at whether lowering the dose of olverembatinib (from 30 or 40 mg to 20 mg every other day) keeps working well for people with chronic myeloid leukemia who have already had a good response. It aims to see if a lower dose can still control the cancer while possibly reducing side effects.
This trial tests the drug olverembatinib alone for people with newly diagnosed chronic phase CML who have not had much prior treatment. It aims to see how well the drug works and what side effects it may cause.
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
This trial tests a new oral drug, olverembatinib, for people with chronic-phase CML that has not responded well to at least two other TKIs, or who have a specific mutation (T315I). The goal is to see if it can control the leukemia better.
Hear when a new Pharmacokinetic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.